Skip to main content

Cepheid Posts Decreased Revenue, Widened Loss in Q1

SAN FRANCISCO, April 23 - Cepheid on Tuesday posted decreased revenues and a widened loss for the first quarter 2002.


For the three months ended March 31, the company reported revenues of $2.4 million, compared with $3.3 million in the same period one year ago. Cepheid said the decrease was due to the loss of $1 million in government contracts.


U.S. product sales rose 49 percent while sales in Europeand the Far Eastdecreased by 62 percent.


"We are moving aggressively to strengthen our European distribution capability in view of the continued weakness in European sales seen in the first quarter," Thomas Gutshall, Cepheid's chairman, said in a statement.


Cepheid also said that net losses widened to $4.9 million, or $.19 a share in the first quarter of 2002, compared with $3.2 million, or $.12 a share one year ago. R&D spending increased roughly $300,000 year-over-year to approximately $4 million.


Cepheid said it has roughly $20.9 million in the bank and plans to burn an average of $1.5 million a month during 2002.


Last week, the company named John Bishop its new CEO.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.